← Back to Screener
Milestone Pharmaceuticals Inc. Common Shares (MIST)
Price$2.09
Favorite Metrics
Price vs S&P 500 (26W)6.01%
Price vs S&P 500 (4W)23.59%
Market Capitalization$258.87M
All Metrics
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)1.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-32.38%
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)6.27%
Net Profit Margin (TTM)-1126.07%
EPS (TTM)$-0.87
10-Day Avg Trading Volume3.71M
EPS Excl Extra (TTM)$-0.87
EPS (Annual)$-0.75
ROI (Annual)-63.72%
Net Profit Margin (5Y Avg)-1148.11%
Cash / Share (Quarterly)$1.00
ROA (Last FY)-55.53%
EBITD / Share (TTM)$-0.77
ROE (5Y Avg)-189.76%
Operating Margin (TTM)-1116.24%
Cash Flow / Share (Annual)$-0.46
P/B Ratio6.20x
P/B Ratio (Quarterly)4.12x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)157.19x
Net Interest Coverage (TTM)-67.69x
ROA (TTM)-81.20%
EPS Incl Extra (Annual)$-0.75
Current Ratio (Annual)8.01x
Quick Ratio (Quarterly)7.83x
3-Month Avg Trading Volume4.15M
52-Week Price Return164.55%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.85
P/S Ratio (Annual)167.44x
Asset Turnover (Annual)0.01x
52-Week High$3.06
Operating Margin (5Y Avg)-1175.64%
EPS Excl Extra (Annual)$-0.75
CapEx CAGR (5Y)-39.58%
Tangible BV CAGR (5Y)20.62%
26-Week Price Return10.00%
Quick Ratio (Annual)7.83x
13-Week Price Return12.24%
Total Debt / Equity (Annual)1.37x
Current Ratio (Quarterly)8.01x
Enterprise Value$243.013
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-39.38%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4078.78%
Cash / Share (Annual)$1.00
3-Month Return Std Dev91.25%
Net Income / Employee (TTM)$-2
ROE (Last FY)-150.97%
Net Interest Coverage (Annual)-67.69x
EPS Basic Excl Extra (Annual)$-0.75
Receivables Turnover (TTM)3.31x
Total Debt / Equity (Quarterly)1.37x
EPS Incl Extra (TTM)$-0.87
Receivables Turnover (Annual)5.90x
ROI (TTM)-33.39%
P/S Ratio (TTM)167.44x
Pretax Margin (5Y Avg)-1148.11%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.94
Price vs S&P 500 (52W)134.72%
Year-to-Date Return8.91%
5-Day Price Return9.45%
EPS Normalized (Annual)$-0.75
ROA (5Y Avg)-60.80%
Net Profit Margin (Annual)-4078.78%
Month-to-Date Return84.87%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-0.74
Operating Margin (Annual)-4019.40%
LT Debt / Equity (Annual)1.37x
ROI (5Y Avg)-68.40%
LT Debt / Equity (Quarterly)1.37x
EPS Basic Excl Extra (TTM)$-0.87
P/TBV (Quarterly)3.24x
P/B Ratio (Annual)4.12x
Pretax Margin (TTM)-1126.07%
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)11.56%
Beta1.16x
Revenue / Share (TTM)$0.01
ROE (TTM)-94.21%
52-Week Low$0.77
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MISTMilestone Pharmaceuticals Inc. Common Shares | 167.44x | — | — | — | $2.09 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Milestone Pharmaceuticals is a biopharmaceutical company developing etripamil, a rapid-onset calcium channel blocker delivered as a nasal spray for cardiovascular conditions. The company is commercializing etripamil for paroxysmal supraventricular tachycardia (PSVT) treatment and has a Phase 2 clinical trial underway for atrial fibrillation with rapid ventricular rate (AFib-RVR).